Evidence, Limitations, and Regulatory Context · Japan
Knee Osteoarthritis and Regenerative Medicine in Japan
This article explains selected evidence, important limitations and Japan’s regulatory context for PRP and cell-based interventions studied in knee osteoarthritis. It also explains how to check public records before relying on any claim. It is written for general readers and assumes no medical background.
Japan Medical is a public-source health information project. This page is educational and does not assess individual circumstances. All sources are listed at the bottom with direct links.
Before You Read
Scope and Information Boundaries
One Condition
This page discusses knee osteoarthritis only. Related knee problems are mentioned only where a cited source raises them directly. Each condition has its own evidence base and its own research literature.
No Generalization
Study results on this page should not be generalized to meniscus tears, ligament injuries, focal cartilage defects, infection, inflammatory arthritis, or other knee problems.
Boundaries
Japan Medical does not diagnose, interpret personal imaging, assess suitability, recommend providers, or arrange appointments. Nothing on this page can determine individual suitability, and the page does not compare providers.
Review Status
Not medically reviewed. Sources are government publications, clinical guidelines and peer-reviewed research. This page is not a substitute for evaluation by a licensed physician.
Global Context
Knee Osteoarthritis in Numbers
The World Health Organization tracks osteoarthritis as a leading cause of years lived with disability. These figures describe the condition this page discusses. With ageing populations and rising obesity and injury rates, prevalence is expected to increase further[1].
The Basics
Knee Osteoarthritis in Brief
Two public reference sources frame the basics used throughout this page.
A Whole-Joint Disease
Osteoarthritis affects the whole joint. It can involve cartilage, bone, the synovium, ligaments and the meniscus, so symptoms can arise from several structures at once[2].
More Than Wear and Tear
NIAMS states the breakdown does not happen because of simple wear and tear. Changes in joint tissue can trigger it, usually gradually[2].
Different for Each Person
Symptoms and their effect on daily function vary widely. Two people with the same diagnosis can experience very different limitations in work, sleep, mood and daily activity[2].
Diagnosis Context
How Knee Osteoarthritis Is Assessed
Assessment combines several sources of information rather than one decisive test. Imaging alone does not determine how much pain a person feels[3]. The UK’s NICE guideline advises diagnosing osteoarthritis clinically, without routine imaging, when typical features are present[4]. Japan Medical does not interpret personal symptoms, X-rays, MRI results, laboratory tests or medical records.
No Single Test
There is no single test for osteoarthritis. Diagnosis pieces together several kinds of information[3].
Clinical Evaluation
Assessment may include a medical history covering symptoms, other conditions and medications, plus a physical examination[3].
Imaging, Sometimes
X-rays can show joint-space and bone changes, though early damage often does not appear. MRI can show soft-tissue damage[3].
Ruling Out Other Causes
Blood tests or joint-fluid samples may be used to look for other explanations of the same symptoms, such as infection or gout[3].
Established Care
Common Evidence-Based Management Options
Management is not a fixed sequence, and choices depend on symptoms, function and personal circumstances. Public guidelines describe options that include education, exercise, weight management where relevant, physical therapy, assistive devices, medicines, selected injections, and surgical assessment in appropriate cases[3][4][5].
Goals of Care
NIAMS describes treatment goals as reducing pain, improving joint function, slowing progression and maintaining quality of life. Surgery is generally considered when other measures have not helped enough[3].
Guideline Context
The AAOS document is a US clinical practice guideline, and NICE is the corresponding UK guideline. Neither is Japanese law or a uniform clinical standard in Japan[5].
No Personal Advice Here
This page gives no doses, drug choices, exercise prescriptions, or individual recommendations. Personal management decisions belong with a licensed physician.
Terminology
PRP and Cell-Based Interventions: What Differs
These categories differ in source material, cell content and processing. Results for one cannot be merged automatically with results for another.
PRP
Platelet-Rich Plasma
Source: a person’s own blood. Contains platelets, not processed cells. Preparation methods vary across providers and studies[5].
Bone Marrow
Concentrate
Source: a person’s own bone marrow. Contains cells. Concentration and handling differ between protocols[6].
Adipose-Derived
Preparations
Source: a person’s own fat tissue. Contains cells. Processing methods are not uniform across studies[6].
Culture-Expanded
Cells
Source: own or donor cells grown in a laboratory. Expansion adds processing steps and protocol differences[6].
Donor-Derived
Cells
Source: another person. Screening and immune considerations differ from own-cell products[6].
Exosomes &
Culture Fluids
Cell-free fluids from cell cultures; contents can vary. US FDA consumer information discusses such products — US regulatory context, not a judgment on Japanese services[13].
Culture-expanded and donor-derived products involve more handling steps than same-day preparations — one more reason study protocols are not directly comparable[6].
Reader’s Guide
How to Read Study Outcomes
Studies measure different things. Two trials can both report positive results while measuring completely different outcomes. Knowing which outcome a number describes changes what the number means.
Pain Scores
Self-reported scales such as VAS. A lower score means less reported pain. Scores are subjective and vary between people.
Function Scores
Composite measures such as WOMAC or KOOS, covering movement and daily activity.
Quality of Life
Broader well-being measures, which do not always move together with pain scores[6].
MRI & Structure
Imaging measures of cartilage and joint structure — a separate question from symptoms[6].
Adverse Events
Reported harms, such as injection-site pain or swelling[6].
Follow-Up Duration
How long participants were observed. Short follow-up limits conclusions about durability[6].
A change in a pain or function score does not by itself demonstrate cartilage restoration. Statistical significance, clinically meaningful change, structural change and symptom change are different concepts — one 2026 analysis reported score gains below the threshold patients can feel[8].
Evidence Review
Evidence Review: Cell-Based Injections
One 2026 meta-analysis pooled 28 peer-reviewed randomized trials of intra-articular cell-based injections for knee osteoarthritis, searching major databases through December 2025. All six panels below refer to this single analysis[6].
Reported Findings
The analysis reported improved scores on some pain measures, including VAS, and on several KOOS function subscales versus controls[6].
Structural Findings
MRI-based WORMS scores showed no consistent structural improvement[6].
Adverse Events
Injection-site pain and joint swelling were more frequent with cell-based injections. Serious complications were uncommon and not significantly different[6].
Limitations
WOMAC and quality-of-life results were not all significantly different. Preparations, cell sources and follow-up periods varied between trials, and heterogeneity remained high[6].
Authors’ Framing
The authors described the effects as symptom-modifying, not structure-modifying[6].
Not Established
The findings may not apply to other products, doses, cell sources or processing methods. The authors called for larger, standardized trials[6].
Evidence Review
Evidence Review: PRP
PRP is made from a person’s own blood and contains platelets and growth factors, but it is not a single standardized product. Preparation methods and study protocols differ, which limits comparison between studies. Results for one preparation cannot be transferred to another[7].
Combination Analysis
A 2026 network meta-analysis of 18 trials with 1,376 participants reported PRP plus hyaluronic acid as the most consistent combination studied for pain and function[7].
Limitation: adding cell concentrates to PRP showed no statistically significant additional benefit in that analysis. The authors called for larger, standardized trials[7].
Exercise Combination & Guideline
A 2026 meta-analysis of PRP with structured exercise reported pain reductions, but evidence certainty was low to very low and functional gains stayed below the threshold patients can feel[8].
Guideline: the AAOS — a US clinical practice guideline — states PRP may reduce pain and improve function in knee osteoarthritis, rating the evidence strength as Limited[5].
Safety Context
Risks, Adverse Events and Unknowns
Risk information here comes from two kinds of sources: the cited trials and regulator consumer information. Three panels separate what was reported, what depends on the product, and what remains unknown.
Reported in the Cited Studies
Injection-site pain and swelling were reported more often with cell-based injections in the 28-trial analysis. Serious complications such as infection were uncommon in that analysis[6].
Product-Dependent Considerations
US FDA consumer information describes possible risks including infection, contamination, inflammatory or immune reactions, and collection- or processing-related problems. US regulatory context; this source does not determine the legal status of a Japanese service[13].
Long-Term Unknowns
Durability and long-term outcomes remain uncertain for the preparations studied. Follow-up in many trials was measured in months rather than years. The cited sources do not establish long-term safety or lasting structural benefit. Consent documents should present known and uncertain risks together[6].
Japan Regulatory Context
Provision Plans in Japan
Japan uses a filing-based framework for regenerative medicine services. Four points explain what a filing involves — and what it does not mean.
Committee Process
Regenerative medicine services in Japan operate under provision plans that pass through review by a certified committee before the service is offered[10].
Filed With the Ministry
Plans are submitted to the national government — the Ministry of Health, Labour and Welfare — before provision begins[10].
Filing Is Not Approval
A filing records that the submission process took place. It does not mean the Ministry has approved the service’s efficacy or safety; accurate wording is filed or submitted[10].
Checkable Details
A plan’s number, procedure name and certified committee appear in the published record. Anyone can search the database directly[10].
Separate Systems
Product Approval and Public Records
The approval system and the public database answer different questions. One evaluates products; the other records filings.
Product Marketing Approval
PMDA marketing approval is a separate, product-specific decision, and approved products are listed in PMDA review reports. The framework includes a conditional, time-limited pathway for certain products[11].
Key distinction: a provision-plan filing is not an approval of efficacy or safety. Product approval cannot be extended to a different product, formulation, processing method, indication or clinic service[10][11].
What the Database Can and Cannot Show
The official database can help check a plan number, procedure name, listed provider, certified committee and publication status. Checking a record is a verification step, not a quality rating[10].
It cannot establish: personal suitability, comparative effectiveness, superiority, guaranteed safety, or guaranteed results. It also cannot confirm that a provider’s current practice matches its filing.
Reader’s Guide
How to Read Health Marketing Claims
Advertising language is designed to persuade. Each phrase below is common in regenerative-medicine marketing — with the reason it cannot, by itself, prove efficacy, safety or suitability.
“Government approved”
Filing is a submission process, not an endorsement of results[10].
“Proven to regrow cartilage”
The cited sources do not establish consistent cartilage restoration[6].
“Nobel Prize technology”
A research award recognizes past discoveries. It does not demonstrate that a specific service works today.
“Hundreds of studies”
Registration and publication counts mix different conditions, designs and quality levels. They are not evidence of efficacy.
“Success story” / “before-and-after”
US FTC guidance treats individual stories as insufficient proof of typical results — US context[12].
“No risk” / “completely safe”
The cited studies report adverse events; no intervention is free of risk[6].
“Advanced” / “world-leading”
Status adjectives carry no verifiable information about outcomes.
“From ¥X” / “limited-time” / “free assessment” / “avoid surgery”
Price and urgency framing says nothing about clinical value. Japan regulates medical advertising domestically[9].
These examples are presented as content-evaluation principles for readers. Japan Medical does not determine whether a specific advertisement complies with applicable law, and no real provider names are shown.
Practical Checklist
Public-Record and Documentation Checklist
Ask for each item directly, then cross-check what can be checked in public records. Written answers make later comparison possible. Japan Medical does not verify providers — it can help locate the relevant public database or cited source.
Check Against the Database
Provision-plan number; procedure name; listed facility; risk class; certified committee. Ask for the number first, then check it yourself. These details appear in the published plan record[10].
Request in Writing
Product or preparation description; cell source; processing; known risks; uncertain risks; follow-up; adverse-event process. Consent documents should describe known and uncertain risks. US FDA consumer information lists similar documentation points — US context[13].
Confirm Before Payment
Total expected cost; possible additional charges; cancellation terms; refund terms; follow-up cost. Get all figures in writing before any payment, and keep copies of everything you sign.
Common Questions
Frequently Asked Questions
Is this page a systematic review?
Does a filed provision plan mean product approval?
Why can different studies report different results?
What can Japan Medical help with?
About This Page
About Japan Medical
Identity. Japan Medical is a public-source health information project. Prepared and published by Japan Medical, it summarizes public health information for general readers and cites public records directly so they can be checked.
Purpose. This page summarizes public information about PRP and cell-based interventions studied in knee osteoarthritis, with their limitations and Japan’s regulatory context. It is educational; it is not medical advice.
Method. Japan Medical prioritizes government publications, regulatory databases, clinical guidelines and peer-reviewed human research. Each factual claim is checked against the linked source, and material corrections are recorded when the page is updated. Source selection follows people-first content principles[14].
Scope and updates. Sources were checked on July 28, 2026, and pages are updated when cited sources change materially. This page contains no clinic rankings, provider recommendations, paid provider placement, or appointment arrangement. Article structured data identifies the title, publisher and update date for machine readers[15].
Corrections. Corrections and questions about cited sources are welcome via WhatsApp or LINE. Material corrections are recorded at update time.
Sources
- World Health Organization — Osteoarthritis fact sheet: https://www.who.int/news-room/fact-sheets/detail/osteoarthritis
- NIAMS — Osteoarthritis overview: https://www.niams.nih.gov/health-topics/osteoarthritis
- NIAMS — Osteoarthritis: Diagnosis, Treatment, and Steps to Take: https://www.niams.nih.gov/health-topics/osteoarthritis/diagnosis-treatment-and-steps-to-take
- NICE NG226 — Osteoarthritis in over 16s: Recommendations (UK guideline): https://www.nice.org.uk/guidance/ng226/chapter/Recommendations
- AAOS — Management of Osteoarthritis of the Knee (Non-Arthroplasty), 3rd ed. (US guideline): https://www.aaos.org/oak3cpg
- Awad G et al., Clinical Rheumatology (2026) — cell-based injections meta-analysis, 28 RCTs: https://pubmed.ncbi.nlm.nih.gov/41863718/
- Luan D et al., Journal of Orthopaedic Surgery and Research (2026) — PRP combination network meta-analysis, 18 RCTs: https://pubmed.ncbi.nlm.nih.gov/42343396/
- Dasdemir KA, Karatas N, Disability and Rehabilitation (2026) — PRP with exercise meta-analysis: https://pubmed.ncbi.nlm.nih.gov/42188836/
- Ministry of Health, Labour and Welfare — medical advertising casebook, 5th ed. (PDF): https://www.mhlw.go.jp/content/001439423.pdf
- Ministry of Health, Labour and Welfare — published regenerative medicine provision plans database: https://saiseiiryo.mhlw.go.jp/published_plan/index/
- PMDA — regenerative medical product review reports: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html
- US FTC — Health Products Compliance Guidance (US context): https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
- US FDA — patient and consumer information about regenerative medicine therapies (US regulatory context): https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
- Google Search Central — creating helpful, reliable, people-first content: https://developers.google.com/search/docs/fundamentals/creating-helpful-content
- Google Search Central — article structured data: https://developers.google.com/search/docs/appearance/structured-data/article
Have a Question About the Article?
Send Japan Medical a general question about the article, its terminology or a cited public record. We can help explain the published information and locate its original source.
General questions about sources and terminology are welcome. Please do not send personal records, images, identification documents or other sensitive information.